Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a clinical-stage biotechnology company developing monoclonal and bispecific antibodies for inflammatory and immune-mediated diseases. Its lead candidate, SL-325, is a DR3-blocking antibody being evaluated for inflammatory bowel disease, initially Crohn’s disease; the company is… From the company’s description.
Over the twelve months to Sep 30, 2026, Shattuck Labs, Inc. reported a net loss of $67.72M. Operations used $49.57M in cash. In fiscal 2025, it reported revenue of $1.00M, down 82.5% from fiscal 2024, and a net loss of $48.81M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Shattuck Labs, Inc. does
In the company’s own words
Shattuck Labs, Inc. (Nasdaq: STTK) is a clinical-stage biotechnology company developing monoclonal and bispecific antibodies for inflammatory and immune-mediated diseases. Its lead candidate, SL-325, is a DR3-blocking antibody being evaluated for inflammatory bowel disease, initially Crohn’s disease; the company is conducting a Phase 1 trial in healthy volunteers and plans a Phase 2 trial in patients. Shattuck is also developing SL-425, a half-life-extended version of SL-325, and preclinical bispecific antibodies designed to target DR3 alongside other immune-disease targets. Its research draws on protein engineering and tumor necrosis factor receptor biology, and its candidates are investigational rather than marketed products. The company relies on third-party manufacturers for production of its drug candidates. Its website is https://www.shattucklabs.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- AUSTIN, TX
- Fiscal year end
- December
- CIK
- 1680367
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Shattuck Labs, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Shattuck Labs, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Shattuck Labs, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Shattuck Labs, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Shattuck Labs, Inc.'s last four quarterly filings that the numbers alone won't show?”